T. Rowe Price Associates’s LeMaitre Vascular LMAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $72.5M | Buy |
755,142
+460,148
| +156% | +$47.2M | 0.01% | 777 |
|
|
2026
Q1 | $32.2M | Buy |
294,994
+4,925
| +2% | +$469K | ﹤0.01% | 905 |
|
|
2025
Q4 | $23.5M | Sell |
290,069
-238,310
| -45% | -$20.5M | ﹤0.01% | 1025 |
|
|
2025
Q3 | $46.2M | Buy |
528,379
+240,652
| +84% | +$21.5M | ﹤0.01% | 827 |
|
|
2025
Q2 | $23.9M | Buy |
287,727
+1,992
| +0.7% | +$166K | ﹤0.01% | 921 |
|
|
2025
Q1 | $24M | Buy |
285,735
+956
| +0.3% | +$88.9K | ﹤0.01% | 910 |
|
|
2024
Q4 | $26.2M | Buy |
284,779
+1,680
| +0.6% | +$162K | ﹤0.01% | 925 |
|
|
2024
Q3 | $26.3M | Buy |
283,099
+3,817
| +1% | +$331K | ﹤0.01% | 936 |
|
|
2024
Q2 | $23M | Buy |
279,282
+273,639
| +4,849% | +$20.1M | ﹤0.01% | 924 |
|
|
2024
Q1 | $375K | Buy |
5,643
+695
| +14% | +$42.9K | ﹤0.01% | 2328 |
|
|
2023
Q4 | $281K | Buy |
4,948
+517
| +12% | +$27.1K | ﹤0.01% | 2405 |
|
|
2023
Q3 | $242K | Buy |
4,431
+469
| +12% | +$27.8K | ﹤0.01% | 2429 |
|
|
2023
Q2 | $267K | Buy |
+3,962
| New | +$242K | ﹤0.01% | 2417 |
|
|
2021
Q4 | – | Sell |
-10,014
| Closed | -$532K | – | 3019 |
|
|
2021
Q3 | $532K | Buy |
10,014
+54
| +0.5% | +$3.04K | ﹤0.01% | 2359 |
|
|
2021
Q2 | $608K | Sell |
9,960
-2,740
| -22% | -$146K | ﹤0.01% | 2297 |
|
|
2021
Q1 | $620K | Sell |
12,700
-18
| -0.1% | -$844 | ﹤0.01% | 2265 |
|
|
2020
Q4 | $515K | Sell |
12,718
-99
| -0.8% | -$3.54K | ﹤0.01% | 2225 |
|
|
2020
Q3 | $417K | Hold |
12,817
| – | – | ﹤0.01% | 2165 |
|
|
2020
Q2 | $338K | Sell |
12,817
-3,148
| -20% | -$82.3K | ﹤0.01% | 2209 |
|
|
2020
Q1 | $398K | Buy |
15,965
+228
| +1% | +$7.04K | ﹤0.01% | 2085 |
|
|
2019
Q4 | $566K | Buy |
15,737
+657
| +4% | +$22.7K | ﹤0.01% | 2112 |
|
|
2019
Q3 | $515K | Buy |
15,080
+117
| +0.8% | +$3.74K | ﹤0.01% | 2085 |
|
|
2019
Q2 | $419K | Hold |
14,963
| – | – | ﹤0.01% | 2179 |
|
|
2019
Q1 | $464K | Buy |
14,963
+2,950
| +25% | +$78.7K | ﹤0.01% | 2142 |
|
|
2018
Q4 | $284K | Sell |
12,013
-3,671
| -23% | -$100K | ﹤0.01% | 2307 |
|
|
2018
Q3 | $608K | Buy |
15,684
+96
| +0.6% | +$3.46K | ﹤0.01% | 2076 |
|
|
2018
Q2 | $522K | Buy |
15,588
+3,417
| +28% | +$122K | ﹤0.01% | 2121 |
|
|
2018
Q1 | $441K | Buy |
12,171
+29
| +0.2% | +$1K | ﹤0.01% | 2133 |
|
|
2017
Q4 | $387K | Buy |
12,142
+3,800
| +46% | +$130K | ﹤0.01% | 2184 |
|
|
2017
Q3 | $312K | Buy |
8,342
+5
| +0.1% | +$170 | ﹤0.01% | 2274 |
|
|
2017
Q2 | $260K | Hold |
8,337
| – | – | ﹤0.01% | 2291 |
|
|
2017
Q1 | $205K | Hold |
8,337
| – | – | ﹤0.01% | 2391 |
|
|
2016
Q4 | $211K | Buy |
+8,337
| New | +$185K | ﹤0.01% | 2370 |
|
Other funds holding LMAT
CCA
CAM
CCM
GCM
T. Rowe Price Associates's LMAT Position: Q2 2026 in Review
T. Rowe Price Associates increased its LeMaitre Vascular (LMAT) stake by 156% in Q2 2026, buying an estimated $47.2M and bringing the position to 755,142 shares worth $72.5M. The position accounts for 0.01% of the portfolio, ranked #777.
T. Rowe Price Associates first reported a position in LMAT in Q4 2016 and has held it in 33 quarters since. 326 funds tracked by Wall St. Rank hold LMAT as of Q2 2026.
- T. Rowe Price Associates held 755,142 shares of LeMaitre Vascular worth $72.5M as of Q2 2026.
- T. Rowe Price Associates bought 460,148 LeMaitre Vascular shares in Q2 2026, an estimated $47.2M.
- LeMaitre Vascular made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #777 holding.
- T. Rowe Price Associates first reported a position in LeMaitre Vascular in Q4 2016 and has held it in 33 quarters since.
- 326 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q2 2026.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.